Figure 6.

A through D, Expression of proliferation markers AKT and Stat3 and their phosphorylated molecules in all 5 lung cancer cell lines treated with losartan, cisplatin, or combined losartan plus cisplatin. No treatment effect on AKT, AKT-p, Stat3, or Stat3-p levels were observed with single agent cisplatin or losartan. Combination losartan and cisplatin significantly reduced AKT, AKT-p, Stat3, and Stat3-p in all cell lines (∗P < .05). Programmed death-ligand (E) was not significantly influenced by either losartan or cisplatin, but combination treatment significantly reduced programmed death-ligand (PDL-1) in all cell lines (P < .05).